ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Melasma With Jessner's Solution vs. Trichloroacetic Acid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00166192
Recruitment Status : Completed
First Posted : September 14, 2005
Last Update Posted : November 14, 2013
Sponsor:
Information provided by (Responsible Party):
Zakiya Rice, Emory University

Brief Summary:
Melasma is an acquired discoloration of the skin characterized by brown patches. Chemical peels using agents such as Jessner's solution and trichloroacetic acid (TCA) are commonly used to treat melasma. A chemical peel involves applying the peeling agent to the skin for a short period. The skin will peel similar to a sunburn, and moisturizers are applied to the skin. Although both agents are well-accepted, there have been no good comparisons of the two agents. The purpose of this study is determine if there is a difference in the effectiveness of these two agents.

Condition or disease Intervention/treatment Phase
Melasma Procedure: Jessner's solution chemical peel Procedure: Trichloroacetic acid chemical peel Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Treatment of Melasma With Jessner's Solution vs. Trichloroacetic Acid: A Comparison of Clinical Efficacy
Study Start Date : January 2008
Actual Primary Completion Date : January 2010
Actual Study Completion Date : November 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Chemical Peel
Split face treatment paradigm
Procedure: Jessner's solution chemical peel Procedure: Trichloroacetic acid chemical peel



Primary Outcome Measures :
  1. Clinical efficacy by clinician's evaluation [ Time Frame: 3 months ]
    Hyperpigmenation Global Score


Secondary Outcome Measures :
  1. Efficacy by subject's evaluation [ Time Frame: 3 months ]
    Hyperpigmentation Global Score



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults > 18 years old
  • Clinical diagnosis of melasma
  • Mental capacity to give informed consent

Exclusion Criteria:

  • Pregnancy
  • H/o allergy to Jessner's solution, tricholoracetetic acid, tretinoin, or hydroquinone
  • Active dermatitis
  • Presence of cutaneous infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00166192


Locations
United States, Georgia
Emory University Dermatology Clinic
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Investigators
Principal Investigator: Carl Washington, MD Emory University Department of Dermatology

Responsible Party: Zakiya Rice, Principal Investigator, Emory University
ClinicalTrials.gov Identifier: NCT00166192     History of Changes
Other Study ID Numbers: IRB00024850
First Posted: September 14, 2005    Key Record Dates
Last Update Posted: November 14, 2013
Last Verified: November 2013

Keywords provided by Zakiya Rice, Emory University:
Melasma
Jessner's solution
Trichloroacetic acid (TCA)

Additional relevant MeSH terms:
Melanosis
Hyperpigmentation
Pigmentation Disorders
Skin Diseases
Pharmaceutical Solutions
Ethanol
Salicylates
Anti-Infective Agents, Local
Anti-Infective Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action